E. Eschwege, A. Basdevant, A. Crine, C. Moisan, and M. Charles, Type 2 diabetes mellitus in France in 2012: Results from the ObEpi survey, Diabetes Metab, vol.41, issue.1, pp.55-61, 2015.

T. A. Ciulla, A. G. Amador, and B. Zinman, Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies, Diabetes Care, vol.26, issue.9, pp.2653-2664, 2003.

C. Delcourt, P. Massin, and M. Rosilio, Epidemiology of diabetic retinopathy: Expected vs reported prevalence of cases in the French population, Diabetes Metab, vol.35, issue.6, pp.431-438, 2009.
URL : https://hal.archives-ouvertes.fr/inserm-00394359

J. Yau, S. L. Rogers, and R. Kawasaki, Global Prevalence and Major Risk Factors of Diabetic Retinopathy, Diabetes Care, vol.35, issue.3, pp.556-564, 2012.

T. Y. Wong, R. Klein, and F. Islam, Diabetic Retinopathy in a Multi-ethnic Cohort in the United States, Am J Ophthalmol, vol.141, issue.3, 2006.

M. C. Leske, S. Wu, A. Hennis, B. Nemesure, L. Hyman et al., Incidence of diabetic retinopathy in the Barbados Eye Studies, Ophthalmology, vol.110, issue.5, pp.86-87, 2003.

S. Sivaprasad, B. Gupta, R. Crosby-nwaobi, and J. Evans, Prevalence of Diabetic Retinopathy in Various Ethnic Groups: A Worldwide Perspective, Surv Ophthalmol, vol.57, issue.4, pp.347-370, 2012.

P. Massin, F. Bandello, and J. G. Garweg, Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study): A 12-month, randomized, controlled, doublemasked, multicenter phase II study, Diabetes Care, vol.33, issue.11, pp.2399-2405, 2010.

D. M. Brown, Q. D. Nguyen, and D. M. Marcus, Long-term Outcomes of Ranibizumab Therapy for Diabetic Macular Edema: The 36-Month Results from Two Phase III Trials, Ophthalmology, vol.120, issue.10, pp.2013-2022, 2013.

Q. D. Nguyen, D. M. Brown, and D. M. Marcus, Ranibizumab for Diabetic Macular Edema, Ophthalmology, vol.119, issue.4, pp.789-801, 2012.

D. S. Boyer, Q. D. Nguyen, D. M. Brown, K. Basu, and J. S. Ehrlich, Outcomes with As-Needed Ranibizumab after Initial Monthly Therapy, Ophthalmology, vol.122, issue.12, 2015.

J. A. Wells, A. R. Glassman, and A. R. Ayala, Bevacizumab, or Ranibizumab for Diabetic Macular Edema, Ophthalmology, vol.123, issue.6, pp.1351-1359, 2016.

F. Ghanchi and C. A. Hazel, South Asian diabetic macular oedema treated with ranibizumab (ADMOR)-real-life experience, Eye, vol.30, issue.1, pp.133-138, 2016.

L. Hrarat, F. Fajnkuchen, and V. Sarda, Efficacy and safety of ranibizumab in diabetic macular edema: real life study, Acta Ophthalmol (Copenh), vol.93, 2015.

N. V. Patrao, S. Antao, and C. Egan, Real-World Outcomes of Ranibizumab Treatment for Diabetic Macular Edema in a United Kingdom National Health Service Setting, Am J Ophthalmol, vol.172, pp.51-57, 2016.

Y. Cécile and . Vc, Données sur le diabète en Guadeloupe, 2015.

. Inserm, Circulation, métabolisme, nutrition. Dossiers d'information: Diabète

L. Sandrine-fosse-edorh, Prévalence du diabète traité pharmacologiquement et disparités territoriales en France en, 2012.

C. Creuzot-garcher, P. Massin, A. Duprez, and K. , Oedèmes maculaires: rapport 2016, 2016.

H. Hammes, Y. Feng, F. Pfister, and M. Brownlee, Diabetic Retinopathy: Targeting Vasoregression, Diabetes, vol.60, issue.1, pp.9-16, 2011.

D. A. Antonetti, A. J. Barber, L. A. Hollinger, E. B. Wolpert, and T. W. Gardner, Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors, J Biol Chem, vol.274, issue.33, pp.23463-23467, 1999.

H. Funatsu, H. Yamashita, T. Ikeda, T. Mimura, S. Eguchi et al., Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema, Ophthalmology, vol.110, issue.9, pp.1690-1696, 2003.

S. Suarez, G. W. Mccollum, C. A. Bretz, R. Yang, M. E. Capozzi et al., Modulation of VEGF-Induced Retinal Vascular Permeability by Peroxisome Proliferator-Activated Receptor, Invest Ophthalmol Vis Sci, vol.55, issue.12, pp.8232-8240, 2014.

S. Nag, A. Kapadia, and D. J. Stewart, Review: Molecular pathogenesis of blood-brain barrier breakdown in acute brain injury: BBB breakdown in acute brain injury, Neuropathol Appl Neurobiol, vol.37, issue.1, pp.3-23, 2011.

J. Wisniewska-kruk, I. Klaassen, and I. Vogels, Molecular analysis of blood-retinal barrier loss in the Akimba mouse, a model of advanced diabetic retinopathy, Exp Eye Res, vol.122, pp.123-131, 2014.

R. N. Frank, Etiologic Mechanisms in Diabetic Retinopathy, In: Retina, pp.1241-1270, 2006.

Y. K. Choi, J. H. Kim, and W. J. Kim, AKAP12 Regulates Human Blood-Retinal Barrier Formation by Downregulation of Hypoxia-Inducible Factor-1, J Neurosci, vol.27, issue.16, pp.4472-4481, 2007.

D. A. Antonetti, A. J. Barber, and S. K. Bronson, Diabetic Retinopathy: Seeing Beyond Glucose-Induced Microvascular Disease, Diabetes, vol.55, issue.9, pp.2401-2411, 2006.

A. Das, P. G. Mcguire, and S. Rangasamy, Diabetic Macular Edema: Pathophysiology and Novel Therapeutic Targets, Ophthalmology, vol.122, issue.7, pp.1375-1394, 2015.

A. Bringmann, T. Pannicke, and J. Grosche, Müller cells in the healthy and diseased retina, Prog Retin Eye Res, vol.25, issue.4, pp.397-424, 2006.

M. Hollborn, S. Dukic-stefanovic, and T. Pannicke, Expression of Aquaporins in the Retina of Diabetic Rats, Curr Eye Res, vol.36, issue.9, pp.850-856, 2011.

T. Yamamoto, K. Hitani, Y. Sato, H. Yamashita, and S. Takeuchi, Vitrectomy for Diabetic Macular Edema with and without Internal Limiting Membrane Removal, Ophthalmologica, vol.219, issue.4, pp.206-213, 2008.

M. Takahashi, Vitreoretinal Relationship in Diabetic Retinopathy: A Biomicroscopic Evaluation, Arch Ophthalmol, vol.99, issue.2, p.241, 1981.

A. Giani, M. Cigada, and N. Choudhry, Reproducibility of Retinal Thickness Measurements on Normal and Pathologic Eyes by Different Optical Coherence Tomography Instruments, Am J Ophthalmol, vol.150, issue.6, pp.815-824, 2010.

T. Horii, T. Murakami, K. Nishijima, A. Sakamoto, M. Ota et al., Optical Coherence Tomographic Characteristics of Microaneurysms in Diabetic Retinopathy, Am J Ophthalmol, vol.150, issue.6, pp.840-848, 2010.

M. Bolz, U. Schmidt-erfurth, G. Deak, G. Mylonas, K. Kriechbaum et al., Optical Coherence Tomographic Hyperreflective Foci, Ophthalmology, vol.116, issue.5, 2009.

A. Couturier, V. Mané, and S. Bonnin, CAPILLARY PLEXUS ANOMALIES IN DIABETIC RETINOPATHY ON OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY: Retina, vol.35, issue.11, pp.2384-2391, 2015.

F. J. Freiberg, M. Pfau, J. Wons, M. A. Wirth, M. D. Becker et al., Optical coherence tomography angiography of the foveal avascular zone in diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Für Klin Exp Ophthalmol, vol.254, pp.1051-1058, 2016.

G. Di, Y. Weihong, and Z. Xiao, A morphological study of the foveal avascular zone in patients with diabetes mellitus using optical coherence tomography angiography

, Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Für Klin Exp Ophthalmol, vol.254, issue.5, pp.873-879, 2016.

C. Wilkinson, F. L. Ferris, and R. E. Klein, Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales, Ophthalmology, vol.110, issue.9, pp.1677-1682, 2003.

R. Klein, M. D. Knudtson, K. E. Lee, R. Gangnon, and B. Klein, The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: The Twenty-five-Year Incidence of Macular Edema in Persons with Type 1 Diabetes, Ophthalmology, vol.116, issue.3, pp.497-503, 2009.

, Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38, BMJ, vol.317, issue.7160, pp.703-713, 1998.

, Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). The Lancet, vol.352, pp.854-865, 1998.

, The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus, N Engl J Med, vol.329, issue.14, pp.977-986, 1993.

, The Relationship of Glycemic Exposure (HbA1c) to the Risk of Development and Progression of Retinopathy in the Diabetes Control and Complications Trial, The Diabetes Control and Complications Trial Research Group, vol.44, pp.968-983, 1995.

D. M. Nathan, J. B. Buse, and M. B. Davidson, Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes, Diabetes Care, vol.32, issue.1, pp.193-203, 2009.

A. Keech, P. Mitchell, and P. Summanen, Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. The Lancet, vol.370, pp.61607-61616, 2007.

A. Gupta, V. Gupta, S. Thapar, and A. Bhansali, Lipid-lowering drug atorvastatin as an adjunct in the management of diabetic macular edema, Am J Ophthalmol, vol.137, issue.4, pp.675-682, 2004.

L. S. Lim and T. Y. Wong, Lipids and diabetic retinopathy, Expert Opin Biol Ther, vol.12, issue.1, pp.93-105, 2012.

G. Lingam and T. Wong, Systemic medical management of diabetic retinopathy, Middle East Afr J Ophthalmol, vol.20, issue.4, p.301, 2013.

R. R. Holman, S. K. Paul, M. A. Bethel, H. Neil, and D. R. Matthews, Long-Term Follow-up after Tight Control of Blood Pressure in Type 2 Diabetes, N Engl J Med, vol.359, issue.15, pp.1565-1576, 2008.

C. A. Kiire, M. Porta, and V. Chong, Medical management for the prevention and treatment of diabetic macular edema, Surv Ophthalmol, vol.58, issue.5, pp.459-465, 2013.

S. J. Kim, R. Equi, and N. M. Bressler, Analysis of Macular Edema after Cataract Surgery in Patients with Diabetes Using Optical Coherence Tomography, Ophthalmology, vol.114, issue.5, pp.881-889, 2007.

S. J. Kim, M. Belair, and N. M. Bressler, Retina, vol.28, issue.6, pp.870-876, 2008.

N. Haddad, J. K. Sun, S. Abujaber, D. K. Schlossman, and P. S. Silva, Cataract Surgery and its Complications in Diabetic Patients, Semin Ophthalmol, vol.29, issue.5-6, pp.329-337, 2014.

J. B. Chae, S. G. Joe, and S. J. Yang, Retina, vol.34, issue.1, pp.149-156, 2014.

D. S. Boyer, Y. H. Yoon, and R. Belfort, Three-Year, Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Diabetic Macular Edema, Ophthalmology, vol.121, issue.10, pp.1904-1914, 2014.

M. Elsawy, . Badawi, and H. A. Khairy, Prophylactic postoperative ketorolac improves outcomes in diabetic patients assigned for cataract surgery, Clin Ophthalmol, p.1245, 2013.

E. Y. Chew, W. E. Benson, and N. A. Remaley, Results after lens extraction in patients with diabetic retinopathy: early treatment diabetic retinopathy study report number 25. Arch Ophthalmol Chic Ill, vol.117, pp.1600-1606, 1960.

T. M. Diep and I. Tsui, Risk factors associated with diabetic macular edema, Diabetes Res Clin Pract, vol.100, issue.3, pp.298-305, 2013.

, Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group, Arch Ophthalmol Chic Ill, vol.103, issue.12, pp.1796-1806, 1960.

M. J. Elman, N. M. Bressler, and H. Qin, Expanded 2-Year Follow-up of Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema, Ophthalmology, vol.118, issue.4, pp.609-614, 2011.

M. J. Elman, L. P. Aiello, and R. W. Beck, Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema, Ophthalmology, vol.117, issue.6, pp.1064-1077, 2010.

M. J. Elman, A. Ayala, and N. M. Bressler, Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt versus Deferred Laser Treatment: 5-Year Randomized Trial Results, Ophthalmology, vol.122, issue.2, pp.375-381, 2015.

P. Mitchell, F. Bandello, and U. Schmidt-erfurth, The RESTORE Study. Ophthalmology, vol.118, issue.4, pp.615-625, 2011.

G. E. Lang, A. Berta, and B. M. Eldem, Two-Year Safety and Efficacy of Ranibizumab 0.5 mg in Diabetic Macular Edema, Ophthalmology, vol.120, issue.10, pp.2004-2012, 2013.

Q. D. Nguyen, S. M. Shah, and A. A. Khwaja, Two-Year Outcomes of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study, Ophthalmology, vol.117, issue.11, pp.2146-2151, 2010.

H. Wang, J. Chhablani, and W. R. Freeman, Characterization of Diabetic Microaneurysms by Simultaneous Fluorescein Angiography and Spectral-Domain Optical Coherence Tomography, Am J Ophthalmol, vol.153, issue.5, pp.861-867, 2012.

A. Jain, J. Collen, A. Kaines, J. Hubschman, S. Schwartz et al., Four-Month Outcomes. Retina, vol.30, issue.10, pp.1622-1626, 2010.

M. Kernt, R. Cheuteu, and E. Vounotrypidis, Focal and panretinal photocoagulation with a navigated laser (NAVILAS®), Acta Ophthalmol (Copenh), vol.89, issue.8, 2011.

I. Kozak, S. F. Oster, and M. A. Cortes, Clinical Evaluation and Treatment Accuracy in Diabetic Macular Edema Using Navigated Laser Photocoagulator NAVILAS, Ophthalmology, vol.118, issue.6, pp.1119-1124, 2011.

R. Liegl, J. Langer, and F. Seidensticker, Comparative Evaluation of Combined Navigated Laser Photocoagulation and Intravitreal Ranibizumab in the Treatment of Diabetic Macular Edema. Vavvas D, PLoS ONE, vol.9, issue.12, p.113981, 2014.

I. Kozak, S. Y. El-emam, and L. Cheng, Retina, vol.34, issue.8, pp.1600-1605, 2014.

K. Luttrull, J. Dorin, and G. , Subthreshold Diode Micropulse Laser Photocoagulation (SDM) as Invisible Retinal Phototherapy for Diabetic Macular Edema: A Review, Curr Diabetes Rev, vol.8, issue.4, pp.274-284, 2012.

H. Schatz, Progressive Enlargement of Laser Scars Following Grid Laser Photocoagulation for Diffuse Diabetic Macular Edema, Arch Ophthalmol, vol.109, issue.11, p.1549, 1991.

H. Funatsu, H. Noma, T. Mimura, S. Eguchi, and S. Hori, Association of Vitreous Inflammatory Factors with Diabetic Macular Edema, Ophthalmology, vol.116, issue.1, pp.73-79, 2009.

W. J. Lee, M. H. Kang, M. Seong, and H. Y. Cho, Comparison of aqueous concentrations of angiogenic and inflammatory cytokines in diabetic macular oedema and macular oedema due to branch retinal vein occlusion, Br J Ophthalmol, vol.96, issue.11, 2012.

T. Yoshimura, K. Sonoda, and M. Sugahara, Comprehensive Analysis of Inflammatory Immune Mediators in Vitreoretinal Diseases, PLoS ONE, vol.4, issue.12, p.8158, 2009.

A. Wenzel, C. Grimm, and M. W. Seeliger, Prevention of photoreceptor apoptosis by activation of the glucocorticoid receptor, Invest Ophthalmol Vis Sci, vol.42, issue.7, pp.1653-1659, 2001.

M. C. Gillies, L. L. Lim, and A. Campain, A Randomized Clinical Trial of Intravitreal Bevacizumab versus Intravitreal Dexamethasone for Diabetic Macular Edema, Ophthalmology, vol.121, issue.12, pp.2473-2481, 2014.

, Safety and Efficacy Study of Dexamethasone Versus Ranibizumab in Patients With Diabetic Macular Edema

G. Querques, F. Darvizeh, L. Querques, V. Capuano, F. Bandello et al., Assessment of the Real-Life Usage of Intravitreal Dexamethasone Implant in the Treatment of Chronic Diabetic Macular Edema in France, J Ocul Pharmacol Ther, vol.32, issue.6, pp.383-389, 2016.

D. Medeiros, M. Alkabes, M. Navarro, R. Garcia-arumí, J. Mateo et al., Dexamethasone Intravitreal Implant in Vitrectomized Versus Nonvitrectomized Eyes for Treatment of Patients with Persistent Diabetic Macular Edema, J Ocul Pharmacol Ther, vol.30, issue.9, pp.709-716, 2014.

I. Zhioua, O. Semoun, F. Lalloum, E. H. Souied, D. Intravitreal et al., Retina, vol.35, issue.7, pp.1429-1435, 2015.

P. A. Campochiaro, Q. D. Nguyen, and G. Hafiz, Aqueous Levels of Fluocinolone Acetonide after Administration of Fluocinolone Acetonide Inserts or Fluocinolone Acetonide Implants, Ophthalmology, vol.120, issue.3, pp.583-587, 2013.

P. A. Campochiaro, D. M. Brown, and A. Pearson, Sustained Delivery Fluocinolone Acetonide Vitreous Inserts Provide Benefit for at Least 3 Years in Patients with Diabetic Macular Edema, Ophthalmology, vol.119, issue.10, pp.2125-2132, 2012.

J. Cunha-vaz, P. Ashton, and R. Iezzi, Sustained Delivery Fluocinolone Acetonide Vitreous Implants, Ophthalmology, vol.121, issue.10, 2014.

M. J. Elman, H. Qin, and L. P. Aiello, Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt versus Deferred Laser Treatment, Ophthalmology, vol.119, issue.11, pp.2312-2318, 2012.

C. Prünte, F. Fajnkuchen, and S. Mahmood, Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study, Br J Ophthalmol, vol.100, issue.6, pp.787-795, 2016.

Y. Yanagida, T. Ueta, . Systemic, . Of, . For et al., Meta-analysis of Randomized Trials. Retina, vol.34, issue.4, pp.629-635, 2014.

N. Rayess, E. Rahimy, and C. P. Shah, Incidence and clinical features of post-injection endophthalmitis according to diagnosis, Br J Ophthalmol, vol.100, issue.8, pp.1058-1061, 2016.

H. El-chehab, L. Corre, A. Giraud, J. Ract-madoux, G. Swalduz et al., Efficacité d'un traitement prophylactique hypotonisant dans l'hypertonie oculaire induite après injections intravitréennes, J Fr Ophtalmol, vol.35, issue.8, pp.614-621, 2012.

S. J. Bakri, J. S. Pulido, C. A. Mccannel, D. O. Hodge, N. Diehl et al., Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab, Eye, vol.23, issue.1, pp.181-185, 2009.

N. Alagöz, C. Alagöz, and I. Y?lmaz, Immediate Intraocular Pressure Changes Following Intravitreal Dexamethasone Implant, J Ocul Pharmacol Ther, vol.32, issue.1, pp.44-49, 2016.

D. M. Brown, U. Schmidt-erfurth, and D. V. Do, Intravitreal Aflibercept for Diabetic Macular Edema, Ophthalmology, vol.122, issue.10, pp.2044-2052, 2015.

S. J. Lee, E. T. Kim, and Y. S. Moon, Intravitreal Bevacizumab Alone versus Combined with Macular Photocoagulation in Diabetic Macular Edema, Korean J Ophthalmol, vol.25, issue.5, p.299, 2011.

M. Michaelides, A. Kaines, and R. D. Hamilton, A Prospective Randomized Trial of Intravitreal Bevacizumab or Laser Therapy in the Management of Diabetic Macular Edema (BOLT Study), Ophthalmology, vol.117, issue.6, pp.1078-1086, 2010.

C. Egan, H. Zhu, and A. Lee, Report 1: baseline characteristics and visual acuity outcomes in eyes treated with intravitreal injections of ranibizumab for diabetic macular oedema, Br J Ophthalmol, vol.101, issue.1, pp.75-80, 2017.

N. M. Bressler, T. S. Chang, and I. J. Suñer, Vision-Related Function after Ranibizumab Treatment by Better-or Worse-Seeing Eye, Ophthalmology, vol.117, issue.4, pp.747-756, 2010.

E. H. Souied, H. Oubraham, G. Mimoun, S. Y. Cohen, S. Quere et al., The TWIN Study. Retina, vol.35, issue.9, pp.1743-1749, 2015.

S. Y. Cohen, L. Dubois, and R. Tadayoni, Results of One-Year's Treatment with Ranibizumab for Exudative Age-related Macular Degeneration in a Clinical Setting, Am J Ophthalmol, vol.148, issue.3, pp.409-413, 2009.

S. Cohen, E. H. Souied, and M. Weber, Patient characteristics and treatment of neovascular age-related macular degeneration in France: the LUEUR1 observational study, Graefes Arch Clin Exp Ophthalmol, vol.249, issue.4, pp.521-527, 2011.

F. G. Holz, F. Bandello, and M. Gillies, Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme, Br J Ophthalmol, vol.97, issue.9, pp.1161-1167, 2013.

R. P. Singh, K. Habbu, J. P. Ehlers, M. C. Lansang, L. Hill et al., The Impact of Systemic Factors on Clinical Response to Ranibizumab for Diabetic Macular Edema, Ophthalmology, vol.123, issue.7, pp.1581-1587, 2016.

. Pauvreté and . Précarité-en-guadeloupe, , 2005.

U. Schmidt-erfurth, G. E. Lang, and F. G. Holz, Three-Year Outcomes of Individualized Ranibizumab Treatment in Patients with Diabetic Macular Edema, Ophthalmology, vol.121, issue.5, pp.1045-1053, 2014.

A. Rabiolo, M. V. Cicinelli, and E. Corbelli, Correlation Analysis between Foveal Avascular Zone and Peripheral Ischemic Index in Diabetic Retinopathy: A Pilot Study. Ophthalmol Retina, 2017.

J. G. Gross and A. R. Glassman, Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial, JAMA, vol.314, p.2137, 1920.

S. B. Bressler, D. Liu, and A. R. Glassman, Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab, JAMA Ophthalmol, vol.135, issue.6, p.558, 2017.

S. A. Regnier, W. Malcolm, J. Haig, and W. Xue, Cost-effectiveness of ranibizumab versus aflibercept in the treatment of visual impairment due to diabetic macular edema: a UK healthcare perspective, Clin Outcomes Res, p.235, 2015.